NASDAQ:EDITEditas Medicine Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Editas Medicine Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $34.92 -0.40 (-1.13 %) (As of 08/14/2020 04:00 PM ET) Add Compare Share Today's Range$34.29Now: $34.92▼$35.6550-Day Range$28.92MA: $31.60▼$36.8452-Week Range$14.01Now: $34.92▼$39.96Volume440,283 shsAverage Volume993,308 shsMarket Capitalization$2.17 billionP/E RatioN/ADividend YieldN/ABeta1.99 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Editas Medicine, Inc. operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops other therapies for eye diseases, such as Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; Retinitis Pigmentosa, a progressive form of retinal degeneration; and Herpes Simplex Virus 1 that causes lifelong infections leading to ocular and oral disease. In addition, the company develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; a strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and a strategic research collaboration and cross-licensing agreement with BlueRock Therapeutics to combine their respective genome editing and cell therapy technologies to discover, develop, and manufacture engineered cell medicines. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 4.2 Analyst's Opinion Consensus RatingEditas Medicine has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 3 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $45.00, Editas Medicine has a potential upside of 28.9% from its current price of $34.90.Amount of Analyst CoverageEditas Medicine has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.1 Community Rank Outperform VotesEditas Medicine has received 268 “outperform” votes. (Add your “outperform” vote.)Underperform VotesEditas Medicine has received 368 “underperform” votes. (Add your “underperform” vote.)Community SentimentEditas Medicine has received 57.86% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Editas Medicine and other stocks. Vote “Outperform” if you believe EDIT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EDIT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldEditas Medicine does not currently pay a dividend.Dividend GrowthEditas Medicine does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Editas Medicine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $96,660.00 in company stock.Percentage Held by InsidersOnly 0.86% of the stock of Editas Medicine is held by insiders.Percentage Held by Institutions81.92% of the stock of Editas Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Editas Medicine are expected to decrease in the coming year, from ($3.11) to ($3.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Editas Medicine is -13.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Editas Medicine is -13.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEditas Medicine has a P/B Ratio of 6.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.2Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.46 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EDIT Previous Symbol CUSIPN/A CIK1650664 Webwww.editasmedicine.com Phone617-401-9000Debt Debt-to-Equity Ratio0.09 Current Ratio6.17 Quick Ratio6.17Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$20.53 million Price / Sales105.92 Cash FlowN/A Price / Cash FlowN/A Book Value$5.12 per share Price / Book6.82Profitability EPS (Most Recent Fiscal Year)($2.68) Net Income$-133,750,000.00 Net Margins-404.88% Return on Equity-56.01% Return on Assets-29.38%Miscellaneous Employees133 Outstanding Shares62,270,000Market Cap$2.17 billion Next Earnings Date11/10/2020 (Estimated) OptionableOptionable $34.92 -0.40 (-1.13 %) (As of 08/14/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive EDIT News and Ratings via Email Sign-up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter. Editas Medicine (NASDAQ:EDIT) Frequently Asked Questions How has Editas Medicine's stock price been impacted by COVID-19? Editas Medicine's stock was trading at $20.27 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, EDIT stock has increased by 72.3% and is now trading at $34.92. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Editas Medicine? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Editas Medicine. When is Editas Medicine's next earnings date? Editas Medicine is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for Editas Medicine. How were Editas Medicine's earnings last quarter? Editas Medicine Inc (NASDAQ:EDIT) issued its quarterly earnings results on Thursday, August, 6th. The company reported ($0.43) EPS for the quarter, beating analysts' consensus estimates of ($0.80) by $0.37. The company had revenue of $10.75 million for the quarter, compared to analyst estimates of $6.34 million. Editas Medicine had a negative return on equity of 56.01% and a negative net margin of 404.88%. The firm's quarterly revenue was up 361.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.69) EPS. View Editas Medicine's earnings history. What price target have analysts set for EDIT? 7 brokers have issued 12 month target prices for Editas Medicine's stock. Their forecasts range from $28.00 to $65.00. On average, they expect Editas Medicine's share price to reach $45.00 in the next year. This suggests a possible upside of 28.9% from the stock's current price. View analysts' price targets for Editas Medicine. Has Editas Medicine been receiving favorable news coverage? Headlines about EDIT stock have trended somewhat negative this week, InfoTrie Sentiment reports. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Editas Medicine earned a news sentiment score of -1.8 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about Editas Medicine. Who are some of Editas Medicine's key competitors? Some companies that are related to Editas Medicine include Repligen (RGEN), Crispr Therapeutics (CRSP), Acceleron Pharma (XLRN), Allogene Therapeutics (ALLO), Adaptive Biotechnologies (ADPT), Spark Therapeutics (ONCE), bluebird bio (BLUE), Iovance Biotherapeutics (IOVA), China Biologic Products (CBPO), Halozyme Therapeutics (HALO), Ablynx (ABLYF), Relay Therapeutics (RLAY), Sorrento Therapeutics (SRNE), Momenta Pharmaceuticals (MNTA) and Denali Therapeutics (DNLI). View all competitors. What other stocks do shareholders of Editas Medicine own? Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include Crispr Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Square (SQ), QUALCOMM (QCOM), Shopify (SHOP) and Paypal (PYPL). Who are Editas Medicine's key executives? Editas Medicine's management team includes the following people: Dr. Charles Albright, Chief Scientific Officer (Age 61)Ms. Cynthia L. Collins, Interim CEO & Director (Age 61)Dr. Feng Zhang, Co-Founder & Scientific Advisory Board MemberDr. George M. Church, Co-Founder & Scientific Advisory Board Member (Age 65)Dr. J. Keith Joung, Co-Founder & Scientific Advisory Board Member When did Editas Medicine IPO? (EDIT) raised $100 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers. What is Editas Medicine's stock symbol? Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT." Who are Editas Medicine's major shareholders? Editas Medicine's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.25%), Sumitomo Mitsui Trust Holdings Inc. (9.05%), Federated Hermes Inc. (3.09%), Goldman Sachs Group Inc. (1.40%), Avidity Partners Management LP (0.96%) and Viking Global Investors LP (0.75%). Company insiders that own Editas Medicine stock include Andrew A F Hack, Charles Albright, Cynthia Collins, Jessica Hopfield, Katrine Bosley and Vickesh Myer. View institutional ownership trends for Editas Medicine. Which major investors are selling Editas Medicine stock? EDIT stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Viking Global Investors LP, First Trust Advisors LP, FMR LLC, Creative Planning, WINTON GROUP Ltd, US Bancorp DE, and PNC Financial Services Group Inc.. Company insiders that have sold Editas Medicine company stock in the last year include Charles Albright, and Cynthia Collins. View insider buying and selling activity for Editas Medicine. Which major investors are buying Editas Medicine stock? EDIT stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Avidity Partners Management LP, Federated Hermes Inc., Goldman Sachs Group Inc., Monashee Investment Management LLC, Tudor Investment Corp Et Al, Bank of America Corp DE, and Russell Investments Group Ltd.. View insider buying and selling activity for Editas Medicine. How do I buy shares of Editas Medicine? Shares of EDIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Editas Medicine's stock price today? One share of EDIT stock can currently be purchased for approximately $34.92. How big of a company is Editas Medicine? Editas Medicine has a market capitalization of $2.17 billion and generates $20.53 million in revenue each year. The company earns $-133,750,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Editas Medicine employs 133 workers across the globe. What is Editas Medicine's official website? The official website for Editas Medicine is www.editasmedicine.com. How can I contact Editas Medicine? Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The company can be reached via phone at 617-401-9000 or via email at [email protected] This page was last updated on 8/14/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
